Outcome of Patients With Relapsed Acute Promyelocytic Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.01.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Koji Sasaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ksasaki1@mdanderson.org. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Tretinoin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, The University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
BACKGROUND: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal therapy for APL relapse is believed to require autologous or allogeneic stem cell transplantation (SCT) based on historical experience. STUDY AIMS: To evaluate the outcome of patients with relapsed APL before and after the era of ATRA-ATO. PATIENTS AND METHODS: We reviewed 61 patients with relapsed APL treated from November 1991 to June 2023; 31 patients (51%) received modern therapy with the combination of ATRA and ATO with and without idarubicin and gemtuzumab ozogamicin (GO). RESULTS: Overall, 56 patients (92%) achieved CR after the first salvage therapy; 20 patients received SCT (10 autologous SCT;10 allogeneic SCT). With a median follow-up time of 138 months, the median survival durations were 32 months and 164 months with historical therapy vs. modern (ATRA-ATO) therapy (P = .035); the 5-year survival rates were 44% vs. 71%. With a 10-month landmark analysis, the median survival durations were 102 months vs. not reached, and the 5-year survival rates were 57% and 70% without SCT vs. with SCT (P = .193). The survival benefit with SCT was more prominent in the historical therapy era. However, patients who received the modern combination therapy of ATRA-ATO with and without idarubicin and GO had similar outcomes without vs. with SCT (P = .848). CONCLUSION: The combination of ATRA-ATO (+/- GO and idarubicin) is a highly effective salvage therapy in relapsed APL. The use of SCT may not be needed after first relapse-second remission but may be considered in subsequent relapses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ksasaki1@mdanderson.org.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Förderung
- NCI NIH HHS
- The University of Texas MD Anderson Cancer Center
Zitieren
APA
Sasaki, K., Ravandi, F., Kadia, T., DiNardo, C. D., Yilmaz, M., Short, N., Jabbour, E., Patel, K. P., Loghavi, S., Pierce, S., Borthakur, G., & Kantarjian, H. (2024). Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.01.015
Vancouver
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, et al. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.01.015
BibTeX
@article{Sasaki2024,
author = {Sasaki, Koji and Ravandi, Farhad and Kadia, Tapan and DiNardo, Courtney D and Yilmaz, Musa and Short, Nicholas and Jabbour, Elias and Patel, Keyur P and Loghavi, Sanam and Pierce, Sherry and Borthakur, Gautam and Kantarjian, Hagop},
title = {Outcome of Patients With Relapsed Acute Promyelocytic Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.01.015}
}
EUVIMED